Trovagene with new data from testing onvansertib with Zytiga for certain prostate cancer

Trovagene will present new clinical data from its Phase 2 trial of onvansertib, in combination with Zytiga (abiraterone acetate)/prednisone, in metastatic Castration-Resistant Prostate Cancer (mCRPC), will be presented as an oral poster at the 20^th Asia-Pacific Prostate Cancer Conference, which will be held August 23-26 in Melbourne, Australia.

The data will be presented in an oral, moderated poster session on Saturday, August 24, 2019 at 1:00 pm (AEDT)